ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0394

Hyperspectral Imaging in Systemic Sclerosis-Raynaud Phenomenon

Akash Gupta1, Shannon Teaw2, Alyssa Williams2, F. Perry Wilson3, Brandon Sumpio4, Bauer Sumpio4 and Monique Hinchcliff5, 1Department of Medicine, Yale University School of Medicine, New Haven, CT, 2Section of Rheumatology, Allergy & Immunology, Department of Medicine, Yale School of Medicine, New Haven, CT, 3Section of Nephrology, Department of Medicine, Yale School of Medicine, New Haven, CT; Department of Medicine Clinical and Translational Research Accelerator Yale School of Medicine, New Haven, CT, 4Division of Vascular Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT, 5Yale School of Medicine, Westport, CT

Meeting: ACR Convergence 2021

Keywords: Imaging, Raynaud's phenomenon, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Raynaud phenomenon (RP), a microcirculatory, vasospastic disorder, may be primary or secondary to an autoimmune disease [e.g., an early indicator of systemic sclerosis (SSc)]. Raynaud phenomenon clinical trials have been hampered by the lack of a robust, feasible, and quantitative methodology for assessing change over time. Hyperspectral imaging (HSI) noninvasively measures oxygenated hemoglobin (oxyHb) and deoxygenated hemoglobin (deoxyHb) concentrations, and oxygen saturation (O2 sat) in the skin microcirculation by visible spectroscopy (a spectrometer quantifies hemoglobin light absorption). Data are depicted as an oxygenation heatmap (Fig. 1). The study goal is to explore the potential role of HSI in quantifying SSc-RP hand microcirculation.

Methods: The Yale University Human Investigation Committee approved this prospective study (HIC# 2000026608) of Yale Scleroderma Program patients and healthy control participants (HC). Patients with SSc completed two patient-reported outcome (PRO) instruments: the Raynaud Condition Score (RCS) and the Cochin Hand Function Scale (CHFS) to assess symptom burden. Then, bilateral palmar HSI (HyperMed™, Waltham, MA) was obtained in a temperature-controlled room (22°C). OxyHb, deoxyHb and O2 sat values were calculated using a default region of interest (ROI) measuring 78 mm2 on the palmar side of the fingertips and palm (for normalization) (Fig. 2). Subjects then underwent a cold provocation challenge whereby hands were submerged in 15°C for one minute, and HSI was subsequently repeated at 0, 10, and 20 minutes (min.). Statistical analysis was performed using the mixed effects model (Stata, College Station, TX).

Results: The mean and standard deviation (SD) age and % female for SSc (n=13) and HC (n=13) participants were 49±22 and 40±13 years (y), and 92% and 94% female, respectively. The mean (SD) SSc duration was 10.9 ± 10.4 y with 69% having limited cutaneous SSc. Thirty eight percent of SSc subjects had prior digital ulcers; none were current. Sixty-two% and 38% of SSc patients were prescribed a calcium channel blocker and statin, respectively. Baseline oxyHb, deoxyHb and O2 sat maps did not significantly differ between SSc and HC participants. However, after cold provocation, images from baseline to 0 min revealed significant reductions in mean slopes of oxyHb and O2 sat for SSc (-0.71, -0.33) compared to HC (-0.22, -0.11; p=0.005, 0.014, respectively). There were no differences in deoxyHb maps between SSc patients and HC immediately post cold challenge. From 0 to 20 min, SSc subjects had more change in oxyHb (p=0.001), deoxyHb (p=0.003), and O2 sat (p< 0.001) compared to HC (Fig. 3).

Conclusion: We showed that HSI is a feasible approach for microcirculation measurement in the hands of SSc patients and HC participants. SSc subjects had a greater decline in oxyHb and O2 sat images from baseline to time 0 (after cold provocation) with significant change in oxyHb, O2 sat, and deoxyHb compared to HC subjects thereafter. These data suggest that HSI technology to assess RP vascular dysfunction is a potential quantitative measure for SSc-RP severity and activity in clinical trials.

Figure 1. Hyperspectral Imaging Heatmap. A representative HSI OxyHb image. Red: higher OxyHb [arbitrary units (AU)]; Blue: lower OxyHb (AU). In this patient, only the left two fingers demonstrated RP color changes.

Figure 2. Region of interest (ROI) on the palmar side of palm (used for normalization) and fingertips.

Figure 3A. Box plot of oxyHb over time in systemic sclerosis (SSc) and healthy control participants (HC) between baseline and during cold provocation challenge and B. Box plot of O2 sat over time in systemic sclerosis (SSc) and healthy control participants (HC) between baseline and during cold provocation challenge.


Disclosures: A. Gupta, None; S. Teaw, None; A. Williams, None; F. Wilson, None; B. Sumpio, None; B. Sumpio, None; M. Hinchcliff, None.

To cite this abstract in AMA style:

Gupta A, Teaw S, Williams A, Wilson F, Sumpio B, Sumpio B, Hinchcliff M. Hyperspectral Imaging in Systemic Sclerosis-Raynaud Phenomenon [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/hyperspectral-imaging-in-systemic-sclerosis-raynaud-phenomenon/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hyperspectral-imaging-in-systemic-sclerosis-raynaud-phenomenon/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology